Hep C Tests Down-Classified By FDA
The IVDs, now moderate-risk class II, had been high-risk class III
Executive Summary
Nucleic acid-based hepatitis C virus (HCV) ribonucleic acid tests and HCV antibody tests were reclassified as moderate-risk class II by the US FDA on 19 November. The agency says the change could spur competition among makers of in vitro diagnostics.
You may also be interested in...
FDA Wants To Put Hep C Tests On 510(k) Pathway
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.